ReviewParasites & vectors2015
Prophylactic and therapeutic DNA vaccines against Chagas disease.
Review in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Integrating Cellular Immune Biomarkers with Machine Learning to Identify Potential Correlates of Protection for aVaccines · 2025Article
- Towards a map of the immune system manipulation network byFrontiers in cellular and infection microbiology · 2025Review
- Article
- Chagas Disease: A Silent Threat for Dogs and Humans.International journal of molecular sciences · 2024Review
- Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications.Pharmaceutics · 2023Review
- Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses againstMicroorganisms · 2023Article
- Exploring the performance of Escherichia coli outer membrane vesicles as a tool for vaccine development against Chagas disease.Memorias do Instituto Oswaldo Cruz · 2023Article
- Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure.Journal of clinical medicine · 2022Review
- Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease.Pharmaceutics · 2022Article
- Review
- Incomplete Recruitment of Protective T Cells Is Associated with Trypanosoma cruzi Persistence in the Mouse Colon.Infection and immunity · 2022Article
- α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model.PLoS neglected tropical diseases · 2021Article
- Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection.PLoS neglected tropical diseases · 2020Article
- Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease.Biochimica et biophysica acta. Molecular basis of disease · 2020Review
- DNA Vaccine Treatment in Dogs Experimentally Infected withJournal of immunology research · 2020Article
- Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine AgainstFrontiers in immunology · 2020Article
- Immunity and vaccine development efforts against Trypanosoma cruzi.Acta tropica · 2019Review
- A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease.NPJ vaccines · 2019Article
- Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is a zoonosis caused by Trypanosoma cruzi in which the most affected organ is the heart. Conventional chemotherapy has a very low effectiveness; despite recent efforts, there is currently no better or more effective treatment available. DNA vaccines provide a new alternative for both prevention and treatment of a variety of infectious disorders, including Chagas disease. Recombinant DNA technology has allowed some vaccines to be developed using recombinant proteins or virus-like particles capable of inducing both a humoral and cellular specific immune response. This type of immunization has been successfully used in preclinical studies and there are diverse models for viral, bacterial and/or parasitic diseases, allergies, tumors and other diseases. Therefore, several research groups have been given the task of designing a DNA vaccine against experimental infection with T. cruzi. In this review we explain what DNA vaccines are and the most recent studies that have been done to develop them with prophylactic or therapeutic purposes against Chagas disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.